Biotech Values

[DewDiligence]

FDA briefing docs for Flibanserin in female hypoactive-sexual-desire disorder (for Friday’s advisory panel):
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM215437.pdf

BI’s own presentation:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM215438.pdf

FDA’s proposed questions for the panel:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM215440.pdf

On first glance, the FDA does not appear to be impressed by the data.